While the dollar amount is not large relative to market cap, the fact that both the CFO and CMO are selling shares simultaneously raises caution. Traders should monitor for any upcoming earnings releases or clinical trial updates that may have prompted this activity. The non-cash grants are routine and not economically significant.
RARE drugs
RARE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $23.02entry
- T+1 · 9mo ago −4.13%α −3.21% · $22.07
- T+5 · 8mo ago −1.78%α −0.57% · $22.61
- T+20 · 8mo ago −16.16%α −8.22% · $19.30
- T+60 · 6mo ago +0.52%α −8.81% · $23.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple executives at Ultragenyx Pharmaceutical, including the CFO and Chief Medical Officer, conducted open-market share sales totaling over $317,000 in the past week, while also receiving non-cash stock awards. The selling activity is concentrated among C-suite insiders and represents a modest but notable cluster.
Key Financial Metrics
Key Facts
- CFO Howard Horn sold 6,925 shares for $157,236 in open-market transactions.
- Chief Medical Officer Eric Crombez sold 7,029 shares for $160,261 in open-market transactions.
- Dennis Karl Huang (executive) had 999 shares withheld for taxes, valued at $23,367.
- All three insiders also received stock awards totaling 28,923 shares (non-cash, $0 value).
- Total open-market sales by insiders: $317,497 over 3 days.
- Sales represent approximately 0.014% of Ultragenyx's $2.2B market cap.
Financial Impact
$317,497 in net open-market insider selling over 7 days
Risk Factors
- Insider selling by top executives can signal lack of confidence in near-term prospects.
- Potential for negative market sentiment despite small absolute size of transactions.
- Risk of misinterpretation due to conflation of non-cash award events with actual selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (7 trades, 7d window) | cluster-RARE-1772581860515 |
Track record
22 reports on RARE
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers